ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance

Acquired resistance through genetic mutations is a major obstacle in targeted cancer therapy, but the underlying mechanisms are poorly understood. Here we studied mechanisms of acquired resistance of chronic myeloid leukemia (CML) to tyrosine kinase inhibitors (TKIs) by examining genome-wide gene expression changes in KCL-22 CML cells versus their resistant KCL-22M cells that acquire T315I BCR-ABL mutation following TKI exposure. Although T315I BCR-ABL is sufficient to confer resistance to TKIs in CML cells, surprisingly we found that multiple drug resistance pathways were activated in KCL-22M cells along with reduced expression of a set of myeloid differentiation genes. Forced myeloid differentiation by all-trans-retinoic acid (ATRA) effectively blocked acquisition of BCR-ABL mutations and resistance to the TKIs imatinib, nilotinib or dasatinib in our previously described in vitro models of acquired TKI resistance. ATRA induced robust expression of CD38, a cell surface marker and cellular NADase. High levels of CD38 reduced intracellular nicotinamide adenine dinucleotide (NAD+) levels and blocked acquired resistance by inhibiting the activity of the NAD+-dependent SIRT1 deacetylase that we have previously shown to promote resistance in CML cells by facilitating error-prone DNA damage repair. Consequently, ATRA treatment decreased DNA damage repair and suppressed acquisition of BCR-ABL mutations. This study sheds novel insight into mechanisms underlying acquired resistance in CML, and suggests potential benefit of combining ATRA with TKIs in treating CML, particularly in advanced phases.

[1]  Correction: ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance , 2015, PLoS genetics.

[2]  M. Roth,et al.  Sorting out functions of sirtuins in cancer , 2014, Oncogene.

[3]  L. Su,et al.  The emerging and diverse roles of sirtuins in cancer: a clinical perspective , 2013, OncoTargets and therapy.

[4]  Martin C. Müller,et al.  Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. , 2013, Blood.

[5]  B. Morris Seven sirtuins for seven deadly diseases of aging. , 2013, Free radical biology & medicine.

[6]  Zhiqiang Wang,et al.  Emerging Roles of SIRT1 in Cancer Drug Resistance. , 2013, Genes & cancer.

[7]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[8]  Johan Auwerx,et al.  Sirtuins as regulators of metabolism and healthspan , 2012, Nature Reviews Molecular Cell Biology.

[9]  R. Bhatia,et al.  Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. , 2012, Blood.

[10]  T. Holyoake,et al.  Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. , 2012, Cancer cell.

[11]  J. Stark,et al.  SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells , 2012, Oncogene.

[12]  M. Roth,et al.  Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. , 2012, Carcinogenesis.

[13]  Zhiqiang Wang,et al.  De Novo Acquisition of BCR-ABL Mutations for CML Acquired Resistance , 2011 .

[14]  S. Digumarthy,et al.  Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.

[15]  D. Tenen,et al.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. , 2010, Blood.

[16]  J. Yee,et al.  BCR-ABL Gene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia* , 2009, The Journal of Biological Chemistry.

[17]  T. Clackson,et al.  AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.

[18]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[19]  B. Brors,et al.  The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence , 2009, Leukemia.

[20]  S. Deaglio,et al.  Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. , 2008, Physiological reviews.

[21]  A. Kauffmann,et al.  High expression of DNA repair pathways is associated with metastasis in melanoma patients , 2008, Oncogene.

[22]  T. Holyoake,et al.  Transcriptional Analysis of Quiescent and Proliferating CD34+ Human Hemopoietic Cells from Normal and Chronic Myeloid Leukemia Sources , 2007, Stem cells.

[23]  Junia V. Melo,et al.  Chronic myeloid leukaemia as a model of disease evolution in human cancer , 2007, Nature Reviews Cancer.

[24]  Fei Huang,et al.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.

[25]  F. Lee,et al.  Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice , 2006, Proceedings of the National Academy of Sciences.

[26]  T. White,et al.  Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. , 2006, Biochemical and biophysical research communications.

[27]  T. White,et al.  Regulation of intracellular levels of NAD: a novel role for CD38. , 2006, Biochemical and biophysical research communications.

[28]  C. Goolsby,et al.  NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. , 2006, Cancer research.

[29]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[30]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[31]  Thomas J. Lamkin,et al.  Retinoic acid‐induced CD38 expression in HL‐60 myeloblastic leukemia cells regulates cell differentiation or viability depending on expression levels , 2006, Journal of cellular biochemistry.

[32]  Hongyue Dai,et al.  Gene expression changes associated with progression and response in chronic myeloid leukemia. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[34]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[35]  C. Sawyers,et al.  Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. , 2005, Blood.

[36]  J. Bennett,et al.  Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993) , 2005, Leukemia & lymphoma.

[37]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[38]  Il-Jin Kim,et al.  Identification of Genes with Differential Expression in Acquired Drug-Resistant Gastric Cancer Cells Using High-Density Oligonucleotide Microarrays , 2004, Clinical Cancer Research.

[39]  B. Druker,et al.  Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib , 2003, Pharmacological Reviews.

[40]  M. Egyed,et al.  Effect of Retinoic Acid Treatment on Cytogenetic Remission of Chronic Myeloid Leukaemia , 2003, Acta Haematologica.

[41]  E. Fibach,et al.  Retinoic Acid Induction of CD38 Antigen Expression on Normal and Leukemic Human Myeloid Cells: Relationship with Cell Differentiation , 2003, Leukemia & lymphoma.

[42]  S. Collins The role of retinoids and retinoic acid receptors in normal hematopoiesis , 2002, Leukemia.

[43]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[44]  D. Housman,et al.  A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  L. Degos,et al.  All trans retinoic acid in acute promyelocytic leukemia , 2001, Oncogene.

[46]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[47]  D. Cockayne,et al.  Signals That Initiate Somatic Hypermutation of B Cells In Vitro1 , 2001, The Journal of Immunology.

[48]  U. Thorsteinsdóttir,et al.  NUP98–HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice , 2001, The EMBO journal.

[49]  F. Malavasi,et al.  Human CD38 and related molecules , 2000 .

[50]  I. Bernstein,et al.  All-trans retinoic acid enhances the long-term repopulating activity of cultured hematopoietic stem cells. , 2000, Blood.

[51]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[52]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. , 1997, Pharmacology & therapeutics.

[53]  Adamson,et al.  All-Trans-Retinoic Acid Pharmacology and Its Impact on the Treatment of Acute Promyelocytic Leukemia. , 1996, The oncologist.

[54]  M. Andreeff,et al.  Retinoic Acid-induced Expression of CD38 Antigen in Myeloid Cells Is Mediated through Retinoic Acid Receptor-α , 1994 .

[55]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.

[56]  P. Lansdorp,et al.  Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. , 1991, Blood.

[57]  F. Malavasi,et al.  CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. , 1990, Journal of immunology.

[58]  I. Olsson,et al.  Myeloid differentiation in liquid cultures of cells from patients with chronic myeloid leukemia: effects of retinoic acid and indomethacin. , 1984, Experimental hematology.

[59]  Peter Lloyd,et al.  Clinical Pharmacokinetics of Imatinib , 2005, Clinical pharmacokinetics.

[60]  M. Baccarani,et al.  Clinical Observations, Interventions, and Therapeutic Trials , 2000 .

[61]  E. Estey,et al.  A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia , 1997, Leukemia.

[62]  M. Andreeff,et al.  Retinoic acid-induced expression of CD38 antigen in myeloid cells is mediated through retinoic acid receptor-alpha. , 1994, Cancer research.

[63]  K. Yamada,et al.  [Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all-trans-retinoic acid]. , 1994, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[64]  I. Miyoshi,et al.  Establishment of a Ph1 chromosome-positive cell line from chronic myelogenous leukemia in blast crisis. , 1983, International journal of cell cloning.